ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.
Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.
Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.
ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.
A summary of an ICER cost-effectiveness analysis published in JMCP found that despite incremental clinical benefits, biologics used to treat asthma have low long-term value for money.
A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.